Stay updated on INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial
Sign up to get notified when there's something new on the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page.

Latest updates to the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page
- Check6 days agoChange DetectedRevision: v3.5.2 updated from v3.5.0.SummaryDifference0.0%

- Check13 days agoChange DetectedPadua, Italy was updated to Padova, Italy in the locations section.SummaryDifference0.0%

- Check21 days agoChange DetectedAdded 'Gastrointestinal stromal tumor' as a disease term and a Resources section linking Genetic and Rare Diseases Information Center to the page.SummaryDifference0.1%

- Check35 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.0%

- Check42 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. The previous revision is no longer active.SummaryDifference0.0%

- Check71 days agoChange DetectedUpdated metadata shows a new revision label (v3.4.2) and added dates (2026-02-05, 2026-12, 2026-01-16, 2026-01). Older notices including the government funding lapse message and the previous revision (v3.4.1) were removed.SummaryDifference0.3%

Stay in the know with updates to INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page.